BEBT-908 DLBCL Treatment: A Milestone Approval ...

By João L. Carapinha

July 8, 2025

The recently published article from BeBetter Med (China) highlights the conditional approval of BEBT-908 DLBCL treatment (ifupinostat hydrochloride, trade name: 贝特琳®/Bertlin) by China’s National Medical Products Administration (NMPA). This inno...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.